苏荠宁黄酮通过抑制PI3K/AKT信号通路拮抗肠上皮细胞凋亡改善小鼠实验性结肠炎

doi:10.12122/j.issn.1673-4254.2025.04.17

南方医科大学学报 ›› 2025, Vol. 45 ›› Issue (4): 819-828.doi: 10.12122/j.issn.1673-4254.2025.04.17

• • 上一篇

苏荠宁黄酮通过抑制PI3K/AKT信号通路拮抗肠上皮细胞凋亡改善小鼠实验性结肠炎

储菲¹(), 陈孝华², 宋博文², 杨晶晶², 左芦根²^,³()

^1.蚌埠医科大学第一附属医院，药剂科，安徽蚌埠 233004
^2.蚌埠医科大学第一附属医院，胃肠外科，安徽蚌埠 233004
^3.炎症相关性疾病基础与转化研究安徽省重点实验室，安徽蚌埠 233030

收稿日期:2025-02-07 出版日期:2025-04-20 发布日期:2025-04-28
通讯作者: 左芦根 E-mail:fiona1215@aliyun.com;zuolugen@126.com
作者简介:储菲，主管药师，E-mail: fiona1215@aliyun.com
基金资助:
国家自然科学基金(82370534);安徽省卫生健康科研项目(AHWJ2022a019);安徽省高校杰出青年科研项目(2022AH020085);安徽省生化药物工程技术研究中心开放课题(2022SYKFD04);安徽省高校中青年教师培养行动项目(JWFX2023032);蚌埠医科大学研究生科研创新项目(Byycxz24020)

Moslosooflavone ameliorates dextran sulfate sodium-induced colitis in mice by suppressing intestinal epithelium apoptosis via inhibiting the PI3K/AKT signaling pathway

Fei CHU¹(), Xiaohua CHEN², Bowen SONG², Jingjing YANG², Lugen ZUO²^,³()

^1.Department of Pharmacy, Bengbu 233030, China
^2.Department of Gastrointestinal Surgery, First Affiliated Hospital of Bengbu Medical University, Bengbu 233004, China, Bengbu 233030, China
^3.Anhui Key Laboratory of Basic and Translational Research on Inflammation-related Diseases, Bengbu 233030, China

Received:2025-02-07 Online:2025-04-20 Published:2025-04-28
Contact: Lugen ZUO E-mail:fiona1215@aliyun.com;zuolugen@126.com
Supported by:
National Natural Science Foundation of China(82370534)

摘要/Abstract

摘要：

目的探讨苏荠宁黄酮（MOS）改善实验性结肠炎的作用和机制。方法通过C57BL/6J小鼠饮用2.5% 葡聚糖硫酸钠（DSS）诱导实验性结肠炎，并采用腹腔注射MOS（200 mg/kg）进行干预。实验小鼠共分为4组（n=6）：WT、WT+MOS、DSS和DSS+MOS组，通过检测小鼠体质量、结肠长度、HE染色、肠屏障功能和TUNEL染色来评估MOS对拮抗结肠炎和肠上皮细胞凋亡的作用。体外通过脂多糖（LPS，100 μg/mL）刺激小鼠结肠类器官，并采用MOS（120 μmol/L）进行干预。体外实验共分为4组：Control、Control+MOS、LPS和LPS+MOS组，以评估MOS对LPS诱导的肠屏障损伤和炎症反应的药理作用。网络药理学分析MOS作用的功能学途径和分子机制，并联合免疫印迹检测验证细胞凋亡相关蛋白的表达及其调控机制。结果体内实验表明MOS治疗改善DSS小鼠的体质量减轻（P<0.05）、DAI评分（P<0.05）、结肠缩短（P<0.05）、结肠组织炎症评分（P<0.05）和促炎因子（TNF-α、IL-1β、IL-6和IFN-γ，P<0.05）的表达。肠屏障功能检测表明，MOS治疗降低血中的FITC-Dextran（P<0.05）和I-FABP的浓度，并增加了肠上皮细胞间紧密连接蛋白的表达（ZO-1和claudin-1，P<0.05）。体外实验显示MOS治疗能够改善LPS诱导的结肠类器官的炎症因子水平和肠上皮细胞屏障的损伤（P<0.05）。免疫印迹结果表明，MOS干预在体内和体外都下调C-caspase3和BAX的表达（P<0.05），并上调抗凋亡蛋白Bcl-2的表达（P<0.05）。机制分析表明，DSS小鼠结肠组织和LPS刺激的结肠类器官的PI3K和AKT蛋白的磷酸化水平都被MOS抑制（P<0.05）。结论 MOS可能通过PI3K/AKT信号抑制肠上皮细胞凋亡，从而改善肠道屏障的完整性并缓解实验性结肠炎。

关键词: 炎症性肠病, 苏荠宁黄酮, 肠上皮细胞凋亡, PI3K/AKT信号

Abstract:

Objective To investigate the effect of moslosooflavone (MOS) for ameliorating dextran sulfate sodium (DSS)-induced colitis in mice and the underlying molecular mechanism. Methods C57BL/6J mice with or without DSS exposure in the drinking water were both randomized into two groups for treatment with intraperitoneal injections with MOS (200 mg/kg) or normal saline for 7 days (n=6). Disease severity of the mice was assessed by observing changes in body weight, colon length, histopathology (HE staining), intestinal barrier function, and TUNEL staining. In the in vitro studies, lipopolysaccharide (LPS)-stimulated mouse colon organoids were treated with MOS (120 μmol/L) for 24 h, and the changes in barrier dysfunction and inflammation were analyzed. Network pharmacology and Western blotting were employed to identify functional pathways and apoptotic protein regulation associated with the therapeutic effect of MOS on colitis. Results In the mouse models of DSS-indcued colitis, MOS treatment significantly reduced body weight loss, disease activity index (DAI) scores and colon shortening, ameliorated colonic histopathological changes and inflammation, and lowered pro-inflammatory cytokine levels (TNF-α, IL-1β, IL-6, and IFN-γ). MOS effectively restored intestinal barrier integrity in the mice by reducing serum FITC-dextran and I-FABP concentrations while enhancing the tight junction proteins (ZO-1 and claudin-1). In the colon organoids, MOS significantly suppressed LPS-induced inflammatory responses and epithelial barrier disruption. Western blotting revealed that MOS downregulated C-caspase-3 and BAX and upregulated Bcl-2 expressions in both models. Mechanistically, MOS suppressed PI3K and AKT phosphorylation in both DSS-treated mouse colonic tissues and LPS-stimulated organoids. Conclusion MOS alleviates experimental colitis in mice by inhibiting intestinal epithelial apoptosis via inhibiting the PI3K/AKT pathway, thereby restoring intestinal barrier integrity and reducing inflammation.

Key words: inflammatory bowel disease, moslosooflavone, intestinal epithelium apoptosis, PI3K/AKT signaling

储菲, 陈孝华, 宋博文, 杨晶晶, 左芦根. 苏荠宁黄酮通过抑制PI3K/AKT信号通路拮抗肠上皮细胞凋亡改善小鼠实验性结肠炎[J]. 南方医科大学学报, 2025, 45(4): 819-828.

Fei CHU, Xiaohua CHEN, Bowen SONG, Jingjing YANG, Lugen ZUO. Moslosooflavone ameliorates dextran sulfate sodium-induced colitis in mice by suppressing intestinal epithelium apoptosis via inhibiting the PI3K/AKT signaling pathway[J]. Journal of Southern Medical University, 2025, 45(4): 819-828.

图/表 9

表1 目标基因引物序列

Tab.1 Primer sequences for the target gene

Gene	Forward (5'-3')	Reverse (5'-3')
TNF-α	CAGGCGGTGCCTATGTCTC	CGATCACCCCGAAGTTCAGTAG
IL-1β	GAAATGCCACCTTTTGACAGTG	TGGATGCTCTCATCAGGACAG
IL-6	TCTATACCACTTCACAAGTCGGA	GAATTGCCATTGCACAACTCTTT
IFN-γ	ACAGCAAGGCGAAAAAGGATG	TGGTGGACCACTCGGATGA
GAPDH	TGGCCTTCCGTGTTCCTAC	GAGTTGCTGTTGAAGTCGCA

图1 MOS对DSS小鼠结肠炎症状的影响

Fig.1 Effect of MOS on symptoms in DSS mice. A: Weight changes. B: DAI scores. C, D: Colon length. E, F: Colonoscopy and endoscopic scores. n=6, *P<0.05 vs WT; #P<0.05 vs DSS.

图2 MOS改善DSS小鼠的结肠黏膜损伤

Fig.2 MOS improves intestinal mucosal damage in DSS-treated mice. A, B: HE staining of mouse colon tissues and the inflammation scores. C: Relative mRNA levels of TNF-α, IL-1β, IL-6 and IFN-γ in the colon tissues. n=6, *P<0.05 vs WT; #P<0.05 vs DSS.

图3 MOS对DSS小鼠的肠屏障功能的影响

Fig.3 Effect of MOS on intestinal barrier function in DSS-treated mice. A, B: Comparison of serum FITC levels and I-FABP among the groups. C: Number of goblet cells. D: AB-PAS staining. E, F: Immunofluorescence assay of ZO-1 and claudin-1 expression. G: Western blotting for claudin-1 and ZO-1 expressions. n=6, *P<0.05 vs WT; #P<0.05 vs DSS.

图4 MOS对DSS小鼠的肠上皮细胞凋亡的影响

Fig.4 Effect of MOS on intestinal epithelium apoptosis in DSS-treated mice. A: TUNEL staining. B: Western blotting for C-caspase-3, Bax and Bcl-2. n=6,*P<0.05 vs WT; #P<0.05 vs DSS.

图5 MOS对LPS诱导的结肠类器官肠上皮细胞凋亡的影响

Fig.5 Effect of MOS on LPS-induced intestinal epithelial cell apoptosis in mouse colon organoids. A: Representative images of colon organoids. B: Number of organoids budding. C: Western blotting for C-caspase-3, Bax and Bcl-2. n=6,*P<0.05 vs Con; #P<0.05 vs LPS.

图6 MOS对LPS诱导的肠类器官屏障功能和炎症反应的影响

Fig.6 Effects of MOS on barrier function and inflammation in LPS-induced intestinal organoids. A, B: Immunofluorescence assay of ZO-1 and claudin-1. C: Western blotting of ZO-1and claudin-1. D: Permeability assay of the intestinal barrier. E: qRT-PCR for detecting mRNA levels of TNF-α, IL-1β, IL-6, and INF-γ in the colonic organoids. n=6, *P<0.05 vs Con; #P<0.05 vs LPS.

图7 网络药理学分析MOS的抗凋亡作用可能和PI3K/AKT信号有关

Fig.7 Network pharmacological analysis of the anti-apoptotic effect of MOS involving PI3K/AKT signaling. A: Venn diagram. B: GO enrichment analysis. C: KEGG enrichment analysis.

图8 MOS干预拮抗肠上皮细胞的凋亡可能和PI3K/AKT信号通路有关

Fig.8 MOS inhibits apoptosis of intestinal epithelial cells possibly through the PI3K/AKT signaling pathway. A: Western blotting of PI3K, p-PI3K, AKT and p-AKT expressions in the colon tissue. B: Western blotting of PI3K, p-PI3K, AKT and p-AKT expressions in the colonic organoids. n=6, *P<0.05 vs WT or Con; #P<0.05 vs DSS or LPS.

参考文献 34

1	Geng ZJ, Zuo LG, Li J, et al. Ginkgetin improved experimental colitis by inhibiting intestinal epithelial cell apoptosis through EGFR/PI3K/AKT signaling[J]. FASEB J, 2024, 38(14): e23817.
2	Torres J, Mehandru S, Colombel JF, et al. Crohn's disease[J]. Lancet, 2017, 389(10080): 1741-55.
3	Nóbrega VG, Silva INN, Brito BS, et al. The onset of clinical manifestations in inflammatory bowel disease patients[J]. Arq Gastroenterol, 2018, 55(3): 290-5.
4	Veauthier B, Hornecker JR. Crohn's disease: diagnosis and management[J]. Am Fam Physician, 2018, 98(11): 661-9.
5	Wu JC, Xu XQ, Duan JQ, et al. EFHD2 suppresses intestinal inflammation by blocking intestinal epithelial cell TNFR1 internalization and cell death[J]. Nat Commun, 2024, 15(1): 1282.
6	Zhu LG, Xie Z, Yang G, et al. Stanniocalcin-1 promotes PARP1-dependent cell death via JNK activation in colitis[J]. Adv Sci, 2024, 11(5): e2304123.
7	Zuo LG, Li J, Ge ST, et al. Bryostatin-1 ameliorated experimental colitis in Il-10^-/- Mice by protecting the intestinal barrier and limiting immune dysfunction[J]. J Cell Mol Med, 2019, 23(8): 5588-99.
8	Gupta M, Mishra V, Gulati M, et al. Natural compounds as safe therapeutic options for ulcerative colitis[J]. Inflammopharm-acology, 2022, 30(2): 397-434.
9	Xie YC, Gong SC, Wang LK, et al. Unraveling the treatment effects of Huanglian Jiedu decoction on drug-induced liver injury based on network pharmacology, molecular docking and experimental validation[J]. BMC Complement Med Ther, 2024, 24(1): 219.
10	Chao WW, Kuo YH, Lin BF. Anti-inflammatory activity of new compounds from Andrographis paniculata by NF-kappaB transactivation inhibition[J]. J Agric Food Chem, 2010, 58(4): 2505-12.
11	Zhang J, Zhao T, Zhang PP, et al. Moslosooflavone protects against brain injury induced by hypobaric hypoxic via suppressing oxidative stress, neuroinflammation, energy metabolism disorder, and apoptosis[J]. J Pharm Pharmacol, 2024, 76(1): 44-56.
12	Li MX, Li MY, Lei JX, et al. Huangqin decoction ameliorates DSS-induced ulcerative colitis: Role of gut microbiota and amino acid metabolism, mTOR pathway and intestinal epithelial barrier[J]. Phytomedicine, 2022, 100: 154052.
13	Zuo LG, Geng ZJ, Song X, et al. Browning of mesenteric white adipose tissue in Crohn's disease: a new pathological change and therapeutic target[J]. J Crohns Colitis, 2023, 17(8): 1179-92.
14	Wang L, Song X, Zhou YQ, et al. Sclareol protected against intestinal barrier dysfunction ameliorating Crohn's disease-like colitis via Nrf2/NF-B/MLCK signalling[J]. Int Immunopharmacol, 2024, 133: 112140.
15	Zuo LG, Li J, Zhang XF, et al. Aberrant mesenteric adipose extracellular matrix remodelling is involved in adipocyte dysfunction in Crohn's disease: the role of TLR-4-mediated macrophages[J]. J Crohns Colitis, 2022, 16(11): 1762-76.
16	Tsai PJ, Huang WC, Hsieh MC, et al. Flavones isolated from scutellariae Radix suppress Propionibacterium acnes-induced cytokine production in vitro and in vivo [J]. Molecules, 2015, 21(1): E15.
17	Song Y, Song Q, Tan FY, et al. Seliciclib alleviates ulcerative colitis by inhibiting ferroptosis and improving intestinal inflammation[J]. Life Sci, 2024, 351: 122794.
18	Marincola Smith P, Choksi YA, Markham NO, et al. Colon epithelial cell TGFβ signaling modulates the expression of tight junction proteins and barrier function in mice[J]. Am J Physiol Gastrointest Liver Physiol, 2021, 320(6): G936-57.
19	Ma J, Zhang JQ, Wang YF, et al. Modified Gegen Qinlian decoction ameliorates DSS-induced chronic colitis in mice by restoring the intestinal mucus barrier and inhibiting the activation of γδT17 cells[J]. Phytomedicine, 2023, 111: 154660.
20	Wei YY, Fan YM, Ga Y, et al. Shaoyao decoction attenuates DSS-induced ulcerative colitis, macrophage and NLRP3 inflammasome activation through the MKP1/NF‑κB pathway[J]. Phytomedicine, 2021, 92: 153743.
21	Yang Y, Zhou XC, Jia GY, et al. Network pharmacology based research into the effect and potential mechanism of Portulaca oleracea L. polysaccharide against ulcerative colitis[J]. Comput Biol Med, 2023, 161: 106999.
22	Xu Y, Wang XC, Jiang W, et al. Porphyra haitanensis polysaccharide-functionalized selenium nanoparticles for effective alleviation of ulcerative colitis[J]. Int J Biol Macromol, 2023, 253(Pt 8): 127570.
23	Turpin W, Lee SH, Garay JAR, et al. Increased intestinal permeability is associated with later development of Crohn's disease[J]. Gastroenterology, 2020, 159(6): 2092-100.e5.
24	Jarret A, Jackson R, Duizer C, et al. Enteric nervous system-derived IL-18 orchestrates mucosal barrier immunity[J]. Cell, 2020, 180(1): 50-63.e12.
25	Qiu Y, Yang H. Effects of intraepithelial lymphocyte-derived cytokines on intestinal mucosal barrier function[J]. J Interferon Cytokine Res, 2013, 33(10): 551-62.
26	Magarian Blander J. Death in the intestinal epithelium-basic biology and implications for inflammatory bowel disease[J]. FEBS J, 2016, 283(14): 2720-30.
27	Subramanian S, Geng H, Tan XD. Cell death of intestinal epithelial cells in intestinal diseases[J]. Sheng Li Xue Bao, 2020, 72(3): 308-24.
28	Liang BX, Zhong YZ, Huang YJ, et al. Underestimated health risks: polystyrene micro- and nanoplastics jointly induce intestinal barrier dysfunction by ROS-mediated epithelial cell apoptosis[J]. Part Fibre Toxicol, 2021, 18(1): 20.
29	Zhang Y, Yang X, Ge XH, et al. Puerarin attenuates neurological deficits via Bcl-2/Bax/cleaved caspase-3 and Sirt3/SOD2 apoptotic pathways in subarachnoid hemorrhage mice[J]. Biomed Pharmacother, 2019, 109: 726-33.
30	Zhang ZQ, Fan K, Meng JJ, et al. Deoxynivalenol hijacks the pathway of Janus kinase 2/signal transducers and activators of transcription 3 (JAK2/STAT-3) to drive caspase-3-mediated apoptosis in intestinal porcine epithelial cells[J]. Sci Total Environ, 2023, 864: 161058.
31	Eskandari E, Eaves CJ. Paradoxical roles of caspase-3 in regulating cell survival, proliferation, and tumorigenesis[J]. J Cell Biol, 2022, 221(6): e202201159.
32	Yang JL, Pi CC, Wang GH. Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells[J]. Biomed Pharmacother, 2018, 103: 699-707.
33	Chen SP, Peng JH, Sherchan P, et al. TREM2 activation attenuates neuroinflammation and neuronal apoptosis via PI3K/Akt pathway after intracerebral hemorrhage in mice[J]. J Neuroinflammation, 2020, 17(1): 168.
34	Yan XD, Tong XY, Jia YR, et al. Baiheqingjin formula reduces inflammation in mice with asthma by inhibiting the PI3K/AKT/NF-κb signaling pathway[J]. J Ethnopharmacol, 2024, 321: 117565.

[1]	徐皓男, 张放, 黄钰莹, 姚其盛, 管悦琴, 陈浩. 百蕊草通过调节肠道菌群和调控EGFR/PI3K/Akt信号通路改善小鼠抗生素相关性腹泻[J]. 南方医科大学学报, 2025, 45(2): 285-295.
[2]	裴月娇, 刘慧敏, 昕宇, 刘波. miR-124通过调控PI3K/AKT信号通路改善睡眠剥夺大鼠认知功能[J]. 南方医科大学学报, 2025, 45(2): 340-346.
[3]	张玉如, 万磊, 方昊翔, 李方泽, 王丽文, 李柯霏, 闫佩文, 姜辉. miR-155-5p介导PIK3R1负调控PI3K/AKT信号通路促进原发性干燥综合征人唾液腺上皮细胞增殖[J]. 南方医科大学学报, 2025, 45(1): 65-71.
[4]	张先恒, 刘健, 韩琦, 陈一鸣, 丁香, 陈晓露. 黄芩清热除痹胶囊通过PTEN/PI3K/AKT信号通路改善痛风性关节炎大鼠的炎症反应及尿酸、脂质代谢失衡[J]. 南方医科大学学报, 2024, 44(8): 1450-1458.
[5]	刘硕, 李静, 吴兴旺. Swertiamarin通过抑制肠上皮细胞细胞凋亡改善TNBS诱导的实验性结肠炎[J]. 南方医科大学学报, 2024, 44(8): 1545-1552.
[6]	向珊, 张宗星, 江露, 刘道忠, 李玮怡, 包卓玛, 田瑞, 陈丹, 袁林. 三百棒通过调控PI3K/Akt信号通路改善胶原诱导性类风湿性关节炎大鼠的血管翳[J]. 南方医科大学学报, 2024, 44(8): 1582-1588.
[7]	王媛媛, 陈腾, 从小凡, 李依然, 陈蕊, 张配, 孙小锦, 赵素容. 扁蒴藤素通过活性氧调控PI3K/AKT通路增强顺铂诱导鼻咽癌细胞凋亡[J]. 南方医科大学学报, 2024, 44(5): 904-912.
[8]	邵荣瑢, 杨子, 张文静, 张诺, 赵雅静, 张小凤, 左芦根, 葛思堂. 茯苓酸缓解小鼠克罗恩病：基于抑制PI3K/AKT信号通路拮抗肠上皮细胞凋亡[J]. 南方医科大学学报, 2023, 43(6): 935-942.
[9]	肖姝喆, 成燕玲, 朱云, 唐芮, 古建标, 兰林, 何志华, 刘丹琼, 耿岚岚, 程旸, 龚四堂. WNT2b高表达的成纤维细胞破坏肠道黏膜屏障[J]. 南方医科大学学报, 2023, 43(2): 206-212.
[10]	高晓阳, 赵晓璐, 张春艳, 颜羽昕, 金蓉, 马月宏. 槲皮素诱导肝星状细胞凋亡：基于调控miR-146影响PI3K/Akt信号通路[J]. 南方医科大学学报, 2023, 43(10): 1725-1733.
[11]	范晓丽, 王娟, 王梨明. 甘草查尔酮A通过调控PI3K/AKT信号通路诱导肺鳞癌细胞周期阻滞[J]. 南方医科大学学报, 2023, 43(1): 111-116.
[12]	刘见荣, 沈卫星, 程海波, 范旻旻, 肖君, 徐长亮, 谭佳妮, 赖岳阳, 余成涛, 孙东东, 李柳. 参白解毒方显著抑制小鼠结直肠腺瘤的形成及癌变：基于PTEN/PI3K/AKT通路[J]. 南方医科大学学报, 2022, 42(10): 1452-1461.
[13]	梁小芳, 杨越, 徐帅帅, 刘映, 褚晗玉, 唐艳, 杨飞. 微囊藻毒素-LR长期低剂量暴露诱导小鼠肾脏结构和功能损伤：基于激活PI3K/AKT信号通路[J]. 南方医科大学学报, 2022, 42(10): 1486-1494.
[14]	吴胜男, 张露, 樊红莲, 黄艳平, 宗巧凤, 高琴, 李正红. PI3K/Akt通路在内吗啡肽-1后处理减轻大鼠心肌缺血再灌注损伤中的作用[J]. 南方医科大学学报, 2021, 41(6): 870-875.
[15]	唐静华, 杨颖, 陈洁, 李廷玉, 代英. 沉默神经元HIF-1α和PTEN的表达对体外培养的大鼠神经元氧糖剥夺损伤的影响[J]. 南方医科大学学报, 2021, 41(12): 1795-1800.

苏荠宁黄酮通过抑制PI3K/AKT信号通路拮抗肠上皮细胞凋亡改善小鼠实验性结肠炎

Moslosooflavone ameliorates dextran sulfate sodium-induced colitis in mice by suppressing intestinal epithelium apoptosis via inhibiting the PI3K/AKT signaling pathway

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

图/表 9

参考文献 34

相关文章 15

编辑推荐

Metrics

本文评价